Health Canada is now reviewing Qalsody (tofersen) as a potential treatment for people with amyotrophic lateral sclerosis (ALS) who carry mutations in the SOD1 gene, according to the therapy’s developer Biogen. The Canadian regulatory authority agreed to review Biogen’s application for the therapy’s approval, with its decision expected in early 2025, according to…
News
EverythingALS has introduced a platform aimed at advancing amyotrophic lateral sclerosis (ALS) research using artificial intelligence (AI) and machine learning — with the ultimate goal of eradicating the disease and restoring lost motor function to those with ALS and other neurodegenerative disorders. The collaborative and technology-enabled platform, dubbed…
When investigational amyotrophic lateral sclerosis (ALS) therapy CNM-Au8 reaches the bloodstream, it attracts a layer of proteins called a corona to its surface that help it more easily reach the brain and last longer in circulation, according to recent research. Developer Clene Nanomedicine says the findings are consistent…
Researchers at Mass General Brigham have started an effort to develop brain-computer interfaces (BCI) for people with neurological diseases or brain injuries, including amyotrophic lateral sclerosis (ALS). BCI technologies rely on a person’s unique brain signaling patterns to interpret their intentions, then use that information to control a device…
Researchers at the University of Waterloo will use a CA$125,000 (about $93,000) grant from the ALS Society of Canada and Brain Canada to better understand how proteins become misplaced in cells and build into the toxic clumps that mark amyotrophic lateral sclerosis (ALS). Led by Dale Martin, PhD,…
Taking part in certain recreational activities, including gardening, golfing, woodworking, and hunting, may increase the risk of developing amyotrophic lateral sclerosis (ALS), especially for men, according to a new study. While the causes of ALS still are not well understood, several risk factors have been identified. There’s evidence…
A disorder such as amyotrophic lateral sclerosis (ALS) can be confusing and traumatic for children, particularly if the person with the disease is a family member or close friend. A new animated short film, “LUKi & The Lights,” seeks to help young people understand and cope with the complexities…
Some 20 U.S. organizations with a focus on amyotrophic lateral sclerosis (ALS) have put their names on a letter that seeks to help shape Congressional funding priorities for the federal legislative fiscal year 2025 to better serve the ALS community. The correspondence from the nonprofits, sent last week, was…
Coave Therapeutics has received a grant from the ALS Association to support the development of its gene therapy candidate CTx-TFEB for amyotrophic lateral sclerosis (ALS). The grant, made through the Lawrence and Isabel Barnett Drug Development Program, is part of the $2.9 million the ALS Association…
Daily treatment with monepantel — a drug widely used in veterinary medicine — was shown to reduce the rate of disease progression by as much as 58% in people with amyotrophic lateral sclerosis (ALS) or motor neuron disease (MND), according to top-line data from a Phase 1 trial.
Recent Posts
- Study finds common medications that could be repurposed to treat ALS
- New eye imaging approach may help distinguish ALS from Alzheimer’s
- After 15 years as an ALS caregiver, I’m still learning from others
- Early PrimeC use slows ALS progression, reduces complication risk
- Learning ALS self-advocacy involves being a little pushy